What Happened
On July 23-24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) convened to evaluate seven bulk peptide drug substances nominated for inclusion on the Section 503A Bulks List. Substances on the Bulks List may be used in compounded drug products provided all other statutory requirements are satisfied. Before the meeting, FDA staff had recommended against adding each of the seven peptides, citing concerns with safety, effectiveness, and the available evidence. Following two days of presentations, public comment, and Committee deliberation, PCAC reached a markedly different conclusion.
By favorable vote, the Committee recommended:
- BPC-157
- TB-500
- KPV
- MOTS-C
- Semax
- Epitalon
Only Emideltide (DSIP) failed to receive a favorable recommendation.
Why It Matters
The Divergence is Noteworthy
The Committee reached a different conclusion than FDA staff on six of seven substances – an uncommon degree of divergence in the advisory committee process. Although FDA retains complete discretion, advisory committee recommendations become part of the administrative record. If the Agency ultimately rejects the Committee’s conclusions, it may need to articulate a reasoned basis for doing so, particularly where the Committee evaluated the same evidence and reached materially different conclusions.
Stakeholders should also recognize that the PCAC recommendations represent one component of FDA’s broader review process. FDA’s ultimate determination will likely reflect not only the advisory committee record, but also the Agency’s scientific, legal, and policy analyses. In a statement following the vote, FDA said the agency “will consider the PCAC’s recommendations, consult USP, and work to issue a proposed rule based on these considerations and all the information the agency has gathered. The public will have an opportunity to submit comments on the proposed rule and the agency will publish a final rule after considering those comments.”
The Committee’s Recommendations Resonate with an Evolving Conversation About Peptides
Historically, FDA’s approach to peptides has largely been defined through restrictions on permissible bulk substances, regulatory interpretations, and enforcement positions rather than affirmative pathways for lawful compounding. The Committee’s recommendations come amid a broader conversation among pharmacists, physicians, compounders, and other stakeholders, including patient demand, existing patterns of clinical use, and questions regarding whether regulated pharmacy compounding may provide a preferable alternative to less regulated markets. The recommendations may influence the regulatory conversation surrounding peptide compounding and are already receiving significant attention from stakeholders. Moreover, advisory committee discussions often become part of the broader policy conversation that can inform future rulemaking, enforcement priorities, and industry expectations.
Regulatory Signals Beyond Formal Rulemaking
FDA’s regulatory approach does not develop solely through final rules. Guidance documents, public statements, enforcement priorities, litigation positions, and other Agency actions can provide meaningful insight into FDA’s interpretation of the law while formal rulemaking remains pending. For companies operating in the peptide space, the practical question is not only what FDA ultimately decides with respect to these nominations, but also how the regulatory environment develops as the Agency continues its review.
Any FDA Decision is Likely to Create Both Opportunity and Risk
Whichever conclusion the Agency ultimately reaches for each substance, the regulatory environment is likely to change. For each peptide, addition to the Bulks List would create a new market pathway with attendant compliance requirements, while reaffirmed prohibition can bring additional scrutiny to compounding practices.
What Businesses Should Be Thinking About Now
Compounding pharmacies, outsourcing facilities, healthcare providers, telehealth companies, peptide manufacturers, suppliers, and investors should be evaluating how potential FDA action could affect their business models and compliance obligations. Key considerations include:
- whether supply chain arrangements and sourcing strategies remain appropriate under potential future regulatory scenarios;
- whether quality systems, adverse event reporting processes, and inspection readiness programs are positioned for increased FDA scrutiny;
- whether promotional materials, clinical claims, and healthcare provider communications align with FDA expectations;
- whether existing telehealth relationships and business models account for potential changes in peptide availability; and
- whether investors and strategic partners understand the regulatory risks and opportunities associated with evolving FDA policy.
Whether FDA ultimately adopts or rejects the Committee’s recommendations, the July 2026 PCAC meeting represents an important inflection point in the regulatory conversation surrounding peptide compounding. Companies that monitor these developments and evaluate their compliance strategies before FDA acts will be better positioned to respond as the regulatory landscape continues to evolve.
